Skip to main content
MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory g

Dr. John Cush RheumNow

4 years ago
MIRROR study lead to pegloticase (PEG) label change - adding MTX as Rx to reduced anti-PEG Abs. Based on 14 refractory gout pts given MTX 15mg/wk (w/ folate) and then PEG IV: 3 nonresponders, 1 dropped out, 10 responded/stayed on Rx x 52 wks w/ less ADAbs https://t.co/BZwY7DpmIb https://t.co/gNhhuhmTG5
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other od

Dr. John Cush RheumNow

4 years ago
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow. https://t.co/ZaWnjxiR3W https://t.co/8CElIxWk1v https://t.co/ZVayc3Qt1r
EULAR/ACR Classification in MDA5+ Myositis Patients

A current analysis suggests that nearly 30% of MDA5 IIM patients m

Dr. John Cush RheumNow

4 years ago
EULAR/ACR Classification in MDA5+ Myositis Patients A current analysis suggests that nearly 30% of MDA5 IIM patients may be missed by the 2017 EULAR/ACR classification criteria for IIM. https://t.co/rS25rL5fGO https://t.co/Yw7sGmPW5G
Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based ag

Dr. John Cush RheumNow

4 years ago
Drugs causing Scleroderma (DASSc) - Anticancer rx made up 42% DASSc & 62.3% case reports. Included: taxane-based agents, bleomycin, vinblastine, imatinib, dacarbazine, pembrolizumab pemetrexed; also HRT romiplostim & eculizumab https://t.co/szQmNPO0eu https://t.co/z4tdP4I1kc
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO
Sponsored by Lilly USA
Listen to Philip Mease

Dr. John Cush RheumNow

4 years ago
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO Sponsored by Lilly USA Listen to Philip Mease and April Armstrong discuss a multidisciplinary approach and importantconsiderations when treating patients with joint and skin concerns. https://t.co/lTfz2kUr51 https://t.co/jVp8Uk0uH5
Longitudinal study of 411 adult fibromyalgia pts showed that 73.2% had depression at enrollment. Higher depression score

Dr. John Cush RheumNow

4 years ago
Longitudinal study of 411 adult fibromyalgia pts showed that 73.2% had depression at enrollment. Higher depression scores at baseline predicted poorer functional outcomes. Effectively treated depression resulted in improved functioning at follow-up. https://t.co/D43r4Z5llU https://t.co/a9EgyJLHza
Head Scratcher? Study of UK Biobank cohort (n=380,380) shows those taking Rx Folate had increased risk of COVID-19 Dx (

Dr. John Cush RheumNow

4 years ago
Head Scratcher? Study of UK Biobank cohort (n=380,380) shows those taking Rx Folate had increased risk of COVID-19 Dx (OR 1.51; 1.42–1.61) and Death (OR 2.64; 2.15–3.24). MTX use (+/- folate) had no increase in COVID or COVID death(1.07;0.57–1.98) https://t.co/MLE1sL7KG2 https://t.co/adoLO9qLON
FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines

Today the FDA authorized the updated Omicron subvariant (BA

Dr. John Cush RheumNow

4 years ago
FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. https://t.co/VzQBFgvAqu https://t.co/r0pQuoDVcn
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.
While hypertension and arthritis are very common disorders, the association between them is unclear.  Analysis of NHANES data suggests that both rheumatoid arthritis (RA) and osteoarthritis (OA) are strongly associated with hypertension (HTN). The NHANES (National Health and Nutrition Examination Survey) of non-pregnant adult, aged ≥ 20 years examined data 48,372 eligible participants between 1999–2018.
Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as autoinflammatory diseases (AID) and some may be unclassifiable, clinically or genetically.
Study of 497 pts referred by general practitioners to rheumatologist (2018-19) showed:
- GP Dx changed by Rheum in 58%

Dr. John Cush RheumNow

4 years ago
Study of 497 pts referred by general practitioners to rheumatologist (2018-19) showed: - GP Dx changed by Rheum in 58% - Low complexity Dx (FM, OA) acct for 50% referrals - 46% of referrals inappropriate - GP correlations w/ Rheum Dx poor (κ < 0.5) https://t.co/q592iHQZbq https://t.co/XyPdtpHQGK
Recent review of AOSD suggests:- AOSD &amp; SJIA are the same- Classify dz as systemic or articular- #MAS occurs in u

Dr. John Cush RheumNow

4 years ago

Recent review of AOSD suggests: - AOSD & SJIA are the same - Classify dz as systemic or articular - #MAS occurs in up to 23% - Yamaguchi & Fautrel criteria are widely used - Cytokines important: IL-1, IL-6, IL-18, IL-37 - only Canakinumab is FDA-approved https://t.co/4ERA56Wqcb https://t.co/FkIWxIrwxX

NICE Guidelines on Gout Diagnosis and Management

NICE (UK) has systematically reviewed current medical evidence and de

Dr. John Cush RheumNow

4 years ago
NICE Guidelines on Gout Diagnosis and Management NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness. https://t.co/ckDrfVAynN https://t.co/jzBviwpxGL
×